Tromsø, Norway, October 29[th], 2025 - ArcticZymes Technologies ASA (OSE: AZT)
and Brenntag Specialties Pharma today announced the signing of an exclusive
distribution agreement for ArcticZymes' SAN-HQ and M-SAN enzyme products across
Europe. Under this agreement, Brenntag will act as the exclusive distributor for
these products, while ArcticZymes will continue to maintain direct relationships
with customers in the region.
This collaboration marks the most recent implementation of ArcticZymes new
channel strategy and will significantly enhance the accessibility of
ArcticZymes' innovative salt-active nuclease in Europe. These products are used
in a broad range of bioprocessing applications including the rapidly growing
areas of gene therapy, vaccine manufacturing, and other advanced therapeutic
modalities.
The SAN-HQ and M-SAN enzymes from ArcticZymes offer technically superior
performance under both physiological and high-salt conditions, providing
reliable and efficient removal of nucleic acids in complex manufacturing
environments. ArcticZymes is the only company to offer specific nuclease
solutions, designed and optimised to work at physiological or high salt
concentrations.
· M-SAN is optimised for use with processes which favour physiological salt
concentrations.
· SAN-HQ is designed for application which required a salt concentration, to
reduce aggregates.
Both enzymes are available in research and GMP-grade formats, ensuring a smooth
transition from development to full-scale commercial manufacturing.
Paul Blackburn, Chief Commercial Officer of ArcticZymes Technologies, commented:
"This partnership with Brenntag represents an important step in expanding our
presence across Europe and making our innovative salt-active nucleases more
accessible to biopharmaceutical customers. Brenntag's strong regional footprint,
technical expertise, and proven customer relationships make them an ideal
partner for our existing commercial team to accelerate growth and support our
mission to enable advanced biomanufacturing."
Joakim Rehné, Regional President, Brenntag Pharma EMEA, added:
"Our partnership with ArcticZymes for SAN HQ and M-SAN HQ marks a milestone in
Brenntag's commitment to the biopharmaceutical industry. By expanding our
portfolio with high-quality enzymes, we support our customers from the early
research phase through to full commercialization."
Through this collaboration, both companies reaffirm their commitment to
supporting the rapidly growing therapeutic bioprocessing market by delivering
high-quality, compliant, and scalable enzyme solutions that meet the evolving
needs of therapeutic manufacturing.
About ArcticZymes Technologies ASA
Headquartered in Tromsø, Norway, ArcticZymes Technologies ASA is a publicly
listed, leading provider of novel and high-quality enzymes for use in molecular
research, diagnostics, and biomanufacturing. With over 30 years of expertise,
the company develops and manufactures salt-active nucleases and other specialty
enzymes inspired by the Arctic environment, enabling robust performance under
demanding process conditions. ArcticZymes is certified to ISO 13485 and
manufactures under relevant ICH GMP standards.
For more information, visit www.arcticzymes.com.
About Brenntag
Brenntag is the global market leader in chemicals and ingredients distribution.
Headquartered in Essen, Germany, the company operates a network of around 600
sites in more than 70 countries and employs over 18,000 people. In 2024,
Brenntag generated sales of EUR 16.2 billion. Through its two global divisions,
Brenntag Essentials and Brenntag Specialties, the company provides a
comprehensive range of industrial and specialty chemicals, technical support,
and supply chain solutions. Brenntag is listed on the Frankfurt Stock Exchange
and included in the DAX, DAX 30 ESG, and DAX ESG Target indices.
For more information, visit www.brenntag.com.
Press Contacts
ArcticZymes Technologies ASA
Steve Dey, Global Director of Product Management and Marketing
E-mail: steve.dey@arcticzymes.com
Website: www.arcticzymes.com
Brenntag SE
Helmut Weintögl, Director Communications EMEA
E-mail: helmut.weintoegl@brenntag.com
Phone: +49 (201) 6496-1339
Website: www.brenntag.com